from
Datamonitor Premium Research Reports187 page (57580 word) report
published Sep 26, 2007
Price
$15,200.00 available for immediate download
Report Overview
Search Inside
About
Datamonitor Premium Research R...
...With the seven triptan brands continuing to dominate acute migraine treatment and Ortho- McNeil s Topamax (topiramate) driving sales in the prophylactic market, seven major market revenues increased by 8.1% from 2005 to $3.7 billion in 2006. The launch of pipeline drugs will only periodically offset genericization of GSK s Imitrex (sumatriptan) and Topamax. Further triptan genericization will dictate market dynamics through to 2016. Nevertheless, the largely under served prophylactic market and additional indications such as menstrual migraine will conti nue to present attractive opportunities to both current and future market players. Coverage: Seven major markets (US, Franc e, Germany, Italy, Spain, UK, and Japan) ...
|
| Report Type: | Report
|
| Industry(ies): | Diversified Services
|
| Free Sample: |
Click Here to Download
|
| Format: | | PDF |  |
|
Datamonitor is a premium business information company specializing in industry analysis. Datamonitor's industry research addresses complex strategic issues by providing unbiased expert analysis and in-depth forecasts across the Automotive, Consumer, Energy, Financial Services, Healthcare & Technology sectors.
